Incidence of tissue toxicities in gamma ray and fission neutron-exposed mice treated with Amifostine

References

• Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 2002; 52: 739–747
   PubMed Web of Science ®Google Scholar
• Brown P E. Mechanism of action of aminothiol radioprotectors. Nature 1967; 213: 363–364
   PubMed Web of Science ®Google Scholar
• Calabro-Jones P M, Fahey R C, Smoluk G D, Ward J F. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V 79-171 cells incubated in medium containing WR-2721. International Journal of Radiation Biology & Related Studies in Physics, Chemistry, and Medicine 1985; 47: 23–27
   PubMed Web of Science ®Google Scholar
• Capizzi R L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Seminars in Oncology 1999; 26: 3–21
   PubMed Web of Science ®Google Scholar
• Glover D, Fox K R, Weiler C, Kligerman M M, Turrisi A, Glick J H. Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy. Pharmacological Therapy 1988; 39: 3–7
   PubMed Web of Science ®Google Scholar
• Grdina D J, Carnes B A, Nagy B. Protection by WR-2721 and WR-151327 against late effects of gamma rays and neutrons. Advances in Space Research 1992; 12: 257–263
   PubMedGoogle Scholar
• Grdina D J, Nagy B, Hill C K, Wells R L, Peraino C. The radioprotector WR-1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis 1985; 6: 929–931
   PubMed Web of Science ®Google Scholar
• Grdina D J, Sigdestad C P, Carnes B A. Protection by WR1065 and WR151326 against fission-neutron-induced mutations at the HGPRT locus in V79 cells. Radiation Research 1989; 117: 500–510
   PubMed Web of Science ®Google Scholar
• Grdina D J, Wright B J, Carnes B A. Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Research 1991; 51: 4125–4130
   PubMed Web of Science ®Google Scholar
• Hall E J, Giaccia J A. Radiobiology for the radiologist. Lippincott, Williams and Wilkins Publishing, Baltimore, MD 2005
   Google Scholar
• Hanson W R, Grdina D J. Radiation-induced DNA Single-strand breaks in the intestinal mucosal cells of mice treated with the radioprotectors WR-2721 or 16-16 dimethyl prostaglandin E2. International Journal of Radiation Biology 1987; 52: 67–76
   Web of Science ®Google Scholar
• Hunter N R, Guttenberger R, Milas L. Modification of radiation-induced carcinogenesis in mice by misonidazole and WR-2721. International Journal of Radiation Oncology Biology Physics 1992; 22: 795–798
   PubMedGoogle Scholar
• Jeong W I, Do S H, Kim T H, Jeong D H, Hong I H, Ki M R, Kwak D M, Lee S S, Jee Y H, Kim S B. acute effects of fast neutron irradiation on mouse liver. Journal of Radiation Research 2007; 48: 233–240
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Basic I, Perrin J, Grdina D J. Antimutagenic effects of radioprotector WR-2721 against fission-spectrum neurons and 60Co gamma-rays in mice. International Journal of Radiation Biology 1992; 61: 387–392
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Murley J S, Baker K L, Grdina D J. Relationship between phosphorylated histone H2AX formation and cell survival in human microvascular endothelial cells (HMEC) as a function of ionizing radiation exposure in the presence or absence of thiol-containing drugs. Radiation Research 2007; 168: 106–114
   PubMed Web of Science ®Google Scholar
• Liu S C, Murley J S, Woloschak G, Grdina D J. Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 1997; 18: 2457–2459
   PubMed Web of Science ®Google Scholar
• Maisin J R, Gerber G B, Vankerkom J, Wambersie A. Survival and diseases in C57BL mice exposed to X-rays or 3.1 MeV neutrons at an age of 7 or 21 days. Radiation Research 1996; 146: 453–460
   PubMed Web of Science ®Google Scholar
• Maisin J R, Mattelin G, Lambiet-Collier M. Chemical protection against the long-term effects of a single whole-body exposure of mice to ionizing radiation: I. Life shortening. Radiation Research 1977; 71: 119–131
   PubMed Web of Science ®Google Scholar
• Mell L K, Malik R, Komaki R, Movsas B, Swann R S, Langer C, Antonadou D, Koukourakis M, Mundt A J. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: A meta-analysis. International Journal of Radiation Oncology Biology Physics 2007; 68: 111–118
   PubMed Web of Science ®Google Scholar
• Milas L, Hunter N, Stephens L C, Peters L J. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Research 1984; 44: 5567–5569
   PubMed Web of Science ®Google Scholar
• Milas L, Murray D, Brock W A, Meyn R E. Radioprotectors in tumor radiotherapy: Factors and settings determining therapeutic ratio. Pharmacology & Therapeutics 1988; 39: 179–187
   PubMedGoogle Scholar
• Murley J S, Kataoka Y, Baker K L, Diamond A M, Morgan W F, Grdina D J. Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha. Radiation Research 2007; 167: 465–474
   PubMed Web of Science ®Google Scholar
• Provinciali M, Ciavattini A, Di Stefano G, Argentati K, Garzetti G G. In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Science 1999; 64: 1525–1532
   PubMedGoogle Scholar
• Ramakrishnan N. N-(2-mercaptoethyl)-1, 3-propanediamine (WR-1065) protects thymocytes from programmed cell death. The Journal of Immunology 1992; 148: 1817–1821
   PubMed Web of Science ®Google Scholar
• Rasey J S, Nelson N J, Mahler P, Anderson K, Krohn K A, Menard T. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 Studies and 35S-WR-2721 Biodistribution. Radiation Research 1984; 97: 598–607
   PubMed Web of Science ®Google Scholar
• Schwartz J L, Giovanazzi S M, Karrison T, Jones C, Grdina D J. 2-(Aminopropyl) amino ethanethiol-mediated reductions in 60Co g-ray and fission-spectrum neutron-induced chromosome damage in V79 cells. Radiation Research 1988; 113: 145–154
   PubMed Web of Science ®Google Scholar
• Takahashi T. 252Cf relative biological effectiveness and inheritable effect of fission neutrons in mouse liver tumorigenesis. Cancer Research 1992; 52: 1948–1953
   PubMed Web of Science ®Google Scholar
• Van Beek M E, Doak R L, Sigdestad C P, Grdina D J. Pathological effects of the radiation protector WR-151327 in mice. Radiation Research 1990; 124: 79–84
   PubMedGoogle Scholar
• Walker R I. Requirements of radioprotectors for military and emergency needs. Pharmacological Therapy 1988; 39: 13–20
   PubMed Web of Science ®Google Scholar
• Yuhas J M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Research 1980; 40: 1519–1524
   PubMed Web of Science ®Google Scholar
• Yuhas J M, Storer J B. Differential chemoprotection of normal and malignant tissues. Journal of the National Cancer Institute 1969a; 42: 331–335
   PubMed Web of Science ®Google Scholar
• Yuhas J M, Storer J B. Chemoprotection against three modes of radiation death in the mouse. International Journal of Radiation Biology 1969b; 15
   Google Scholar